Skip to main content

LLS Investment Pays Off: FDA Approves Immunotherapy for Blood Cancer Patients

Rye Brook, N.Y. (August 30, 2017) – Today heralds a new era in cancer treatment with the U.S. Food and Drug Administration (FDA) approval of a new, cutting-edge gene therapy that reprograms a patient’s immune system to find and kill cancer cells.  This highly personalized therapy known as Kymriah (previously CTL019 or tisagenlecleucel-T) signifies the promise of CAR (chimeric antigen receptor) T-cell immunotherapy, an approach that The Leukemia & Lymphoma Society (LLS) recognized early on held great promise for blood cancer patients.

 In fact, LLS invested more than $20 million in research for this groundbreaking advance over the past two decades through multiple grants awarded to Carl June, M.D., and his team at the University of Pennsylvania and Children’s Hospital of Philadelphia, who pioneered this treatment. Novartis licensed the therapy from Penn in 2016.

 LLS has also invested an additional $20 million to support CAR-T advances at other institutions, including Kite Pharma’s KTE-C19 (Axi-cel), also currently under review by the FDA for patients with lymphoma. LLS partnered with Kite Pharma to support its Phase 3 clinical trial since 2015 through its Therapy Acceleration Program® (TAP).

 After receiving a unanimous recommendation from a review panel in July, the FDA approved Kymriah today for the treatment of pediatric and young adults 25 years of age and younger with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). More than 3,100 children and adolescents per year are diagnosed with ALL. The overall survival for ALL in children exceeds 85 percent, with these children undergoing between two and a half to three years of intense chemotherapy treatments. However, even patients who achieve an initial response to standard therapy will eventually relapse, and the prognosis is extremely poor for these patients. This CAR-T therapy is designed for those patients who have not responded to multiple previous treatments or are unable to remain in remission from their cancer.

 “This is truly an exciting new day for cancer patients,” said Louis J. DeGennaro, Ph.D., LLS president and chief executive officer. “LLS recognized the promise of this innovative approach to treatment nearly 20 years ago. We first began to see remarkable outcomes for some of these patients in 2010 leading us to increase our funding of CAR-T therapy by supporting more than 10 major laboratories developing this method. We at LLS are extremely gratified to witness this lifesaving treatment approved so it is accessible to even more patients who desperately need new options.”

 The FDA’s approval of Kymriah is based on positive data from a clinical trial showing that 83 percent of the patients treated achieved a complete response rate.

 LLS is now funding the next generation of CAR-T therapy, where we anticipate the method will be useful in many different blood cancers, and perhaps even other major tumors that are difficult to treat such as brain, lung and colon cancer.

 About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

 Founded in 1949 and headquartered in Rye Brook, NY, LLS has chapters throughout the United States and Canada. To learn more, visit Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

 For additional information visit Follow us on FacebookTwitter, and Instagram.

Contact: Andrea Greif